SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid community debate about its technology and future prospects, with some users expressing skepticism about eVTOL capabilities and range limitations. Bullish investors are pointing to upcoming events like the California International Air Show and potential military contracts as catalysts for growth. A possible collaboration with Tesla has also surfaced as a point of discussion among investors.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community discusses potential catalysts including upcoming news, partnerships, and the possibility of a major exchange listing. Bullish sentiment is fueled by comparisons to early XRP and anticipation of the Zebec Super App launch. Many believe ZBCN is positioned for significant growth and real-world adoption within the evolving financial landscape.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crypto, CAW, is trending due to community enthusiasm around its meme-based identity, "crow with knife," and its expansion across multiple chains. Community members highlight its strong community and deflationary aspects, with many urging others to add it to their watchlist. Bullish sentiment and repetitive "caw caw" messaging dominate the conversation.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network ($REACT) is trending amid community excitement around its cross-chain automation capabilities and the upcoming sunsetting of $PRQ, which some believe has been suppressing its price. The community is also anticipating new exchange listings and marketing campaigns, while highlighting its strong technology and staking rewards. Discussions include potential price targets and the belief that $REACT is an undervalued gem with significant long-term potential.

Roundhill ETF Trust - Roundhill WeeklyPay Universe ETF

Roundhill WeeklyPay™ Universe ETF

The Roundhill WeeklyPay™ Universe ETF ($WPAY) is trending as investors discuss its weekly dividend payouts and compare it to other high-yield ETFs. Community members are actively sharing dividend amounts and payout schedules, while also debating its valuation and potential for NAV erosion. Some are rotating into $WPAY from other dividend plays, drawn to its promise of consistent income.

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

Glaukos Corporation

Glaukos ($GKOS) is trending due to positive Phase 3 trial results for its iDose TR glaucoma treatment, which met primary efficacy endpoints and showed a favorable safety profile. The community is actively discussing the potential for this innovative drug delivery system to disrupt the glaucoma treatment market. Analysts are updating ratings and price targets, reflecting optimism about Glaukos's pipeline and market position in ophthalmic therapies.

Investment Managers Series Trust II - Tradr 2X Long UPST Daily ETF

Tradr 2X Long UPST Daily ETF

Traders are actively discussing $UPSX, a 2x leveraged ETF for Upstart, with many highlighting it as a way to amplify potential gains from $UPST, especially amid anticipation of future rate cuts. The community is weighing the risks and rewards of using the ETF, with some expressing concerns about its correlation to the underlying stock and others seeing it as a potential high-reward play. Overall sentiment leans bullish, with some expecting a significant move if $UPST rebounds.

The Hershey Co. engages in the manufacture and marketing of chocolate, sweets, mints and confectionery products. The firm operates through the following segments: North America Confectionery, North America Salty Snacks and International. The North America Confectionery segment is responsible for the traditional chocolate and non-chocolate confectionery market position of the company, as well as its grocery and snacks market positions, in the United States and Canada. The North America Salty Snacks segment is responsible for the salty snack products in the United States. The International segment includes the combination of all other operating segments, including those geographic regions where the company operates outside of North America. Its brands include Hershey's, Reese's, and Kisses. The company was founded by Milton S. Hershey in 1894 and is headquartered in Hershey, PA.

Hershey Company

HSY is trending amid reports of a potential takeover by Mondelez, driving speculation and a notable price surge. While some traders are betting on a continued rise, others anticipate a pullback if the deal doesn't materialize, given concerns about high cocoa prices and potential market overvaluation.

Morgan Stanley operates as a global financial services company. The firm provides investment banking products and services to its clients and customers including corporations, governments, financial institutions, and individuals. It operates through the following segments: Institutional Securities, Wealth Management, and Investment Management. The Institutional Services segment provides financial advisory, capital-raising services, and related financing services on behalf of institutional investors. The Wealth Management segment offers brokerage and investment advisory services covering various types of investments, including equities, options, futures, foreign currencies, precious metals, fixed-income securities, mutual funds, structured products, alternative investments, unit investment trusts, managed futures, separately managed accounts, and mutual fund asset allocation programs. The Investment Management segment provides equity, fixed income, alternative investments, real estate, and merchant banking strategies. The company was founded by Harold Stanley and Henry S. Morgan in 1924 and is headquartered in New York, NY.

Morgan Stanley

Morgan Stanley ($MS) is trending due to a mix of factors, including unusual options activity and analyst ratings adjustments. Community discussions include call options activity, potential share buybacks, and its performance relative to peers in the financial sector. Some traders are noting technical indicators and potential entry points, while others discuss the broader market context.

Tenable Holdings, Inc. engages in the development of security software solutions. It offers Cyber Exposure which is a discipline for managing and measuring cybersecurity risk in the digital era. Its products include tenable.io, tenable.sc, tenable.ot, and nessus professional. The firm delivers solutions in the field of application security, cloud security, compliance, energy, finance, healthcare, and retail. The company was founded by John C. Huffard, Jr. and Renaud M. Deraison in 2002 and is headquartered in Columbia, MD.

Tenable Holdings Inc

Tenable Holdings is trending amid discussions of its potential as an AI protection acquisition target and overall cybersecurity sector dynamics. Community members are weighing the company's merits against competitors, with some expressing disappointment in its muted market response despite positive earnings, while others suggest it's a hidden gem. Additionally, recent analyst rating adjustments and price target updates are contributing to the ongoing conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Altai Capital Management is reportedly preparing to launch a board fight at medical device company OraSure Technologies (OSUR).The hedge fund is one of the biggest owners of OraSure and built up its stake from 3% at the end of June to 5% in recent weeks, Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/transactional/altai-capital-lays-groundwork-board-fight-orasure-technologies-sources-say-2025-09-09/">reported</a>, citing two people familiar with the matter.The larger stake allows Altai to press its case for board representation more forcefully, the people told Reuters. Two OraSure directors will stand for reelection at next year's annual meeting, and Altai is likely to nominate two candidates, including its founder, Rishi Bajaj, at some point, the report stated. Bajaj last year suggested that an investor with experience in capital allocation should join the OraSure board, the sources told Reuters.Shares of the company traded 2% higher at the time of writing. On Stocktwits, retail sentiment regarding <a href="https://stocktwits.com/symbol/OSUR">OSUR stock</a> remained in ‘bearish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:573/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_12_44_48_PM_png_7a065a0f80.webp" alt="OSUR's Sentiment Meter and Message Volume as of 12:45 p.m. ET on Sept. 9, 2025 | Source: Stocktwits" width="573" height="62"><figcaption>OSUR's Sentiment Meter and Message Volume as of 12:45 p.m. ET on Sept. 9, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes it’s ‘good news’.<stembedurl>https://stocktwits.com/Gantz7/message/627948069</stembedurl>However, another user cheered for the Altai founder.<stembedurl>https://stocktwits.com/AnonMav/message/627979684</stembedurl>Last month, Reuters reported that OraSure Technologies (OSUR) received a letter from healthcare entrepreneur Ron Zwanziger stating that he may pursue a more "adversarial path" if the board continues to resist his offer to buy the company.Zwanziger made an unsolicited all-cash offer to buy OraSure for between $3.50 and $4.00 a share in June but was rebuffed. The entrepreneur stated in his letter that other investors have grown concerned and reached out to him."If the board is not willing to entertain a collaborative discourse, we will be left with no choice but to consider all alternatives available," the letter <a href="https://stocktwits.com/news-articles/markets/equity/orasure-receives-warning-from-ron-zwanziger/chssxJ9RdS9">said</a>, without detailing the alternative options. "We would prefer to work together with you in a collaborative fashion to realize the full value potential for all shareholders, rather than pursuing a more adversarial path," the letter stated, as per the report. However, Altai and Zwanziger are not working together, Reuters said on Tuesday.For the three months through the end of June, OraSure’s total net revenues fell 43% year-on-year to $31.24 million, while diluted and adjusted loss per share stood at $0.19 compared to a profit of $0.08 in the corresponding quarter of 2024.OSUR stock is down 8% this year and approximately 21% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gary-black-expects-tesla-q3-deliveries-to-exceed-wall-street-estimates-but-sees-full-year-numbers-slip/chwK7ojRdtl">Gary Black Expects Tesla Q3 Deliveries To Exceed Wall Street Estimates But Sees Full-Year Numbers Slip: Retail’s Divided On Stock Performance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Hedge Fund Reportedly Prepares To Launch Board Fight At OraSure Technologies: Retail Investors Believe It’s Good News

Altai Capital Management is one of the largest owners of OraSure and has increased its stake from 3% at the end of June to 5% in recent weeks, in an effort to press for board representation, Reuters reported.  

Equity

Altai Capital Management is one of the largest owners of OraSure and has increased its stake from 3% at the end of June to 5% in recent weeks, in an effort to press for board representation, Reuters reported.  


Medical device company OraSure Technologies (OSUR) received a letter from healthcare entrepreneur Ron Zwanziger on Monday stating that he may pursue a more "adversarial path" if the board continues to resist his offer to buy the company, Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/healthcare-entrepreneurs-letter-threatens-adversarial-path-after-orasure-tech-2025-08-25/">reported</a> on Monday.Zwanziger made an unsolicited all-cash offer for the company earlier in the summer but was rebuffed. The entrepreneur stated in his letter that other investors have grown concerned and reached out to him, as per the report."If the board is not willing to entertain a collaborative discourse, we will be left with no choice but to consider all alternatives available," the letter said, without detailing the alternative options. "We would prefer to work together with you in a collaborative fashion to realize the full value potential for all shareholders, rather than pursuing a more adversarial path," the letter read, as per the report.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OSUR">OSUR stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:624/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_25_at_2_07_26_PM_png_4f028f580f.webp" alt="OSUR's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Aug. 25, 2025 | Source: Stocktwits" width="624" height="63"><figcaption>OSUR's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Aug. 25, 2025 | Source: Stocktwits</figcaption></figure>Zwanziger submitted a proposal to buy OraSure for between $3.50 and $4.00 a share in June, the report said. The stock currently trades below these levels. "As time passes without any productive engagement between ourselves, not only do your cash reserves and share price decline, but our offer price may be lowered or withdrawn," the letter said.The entrepreneur also highlighted in his letter that the company’s second-quarter revenue dropped, and its share repurchase program in March ‘failed’ to boost its share price, the report said.For the three months through the end of June, the firm’s total net revenues fell 43% year-on-year to $31.24 million, while diluted and adjusted loss per share stood at $0.19 compared to a profit of $0.08 in the corresponding quarter of 2024. &nbsp;OSUR stock is down by 12% this year and by about 28% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/valneva-stock-tumbles-after-us-fda-suspension-of-ixchiq-license/chssvsiRdSe">Valneva Stock Tumbles 19% After FDA Suspension Of Ixchiq License In US, Wall Street Divided On The Impact</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

OraSure Receives Warning From Ron Zwanziger: Entrepreneur Warns Of Adversarial Path If Board Continues To Refuse Buyout Offer

Zwanziger made an unsolicited all-cash offer for the company earlier in the summer but was rebuffed.

OraSure Technologies (OSUR) Reports Q2 Loss, Beats Revenue Estimates

OraSure (OSUR) delivered earnings and revenue surprises of -26.67% and +2.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates

Smart Money Move: John Kenny Grabs $100K Worth Of OraSure Technologies Stock

OraSure Technologies Appoints New Independent Director

The latest update is out from Orasure Technologies ( ($OSUR) ). OraSure Technologies, Inc. has expanded its Board of Directors from six to seven me...

KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400...

OraSure Technologies (OSUR, $6.14) RSI Indicator left the oversold zone on March 27, 2024

This is a signal that OSUR's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

OraSure Technologies (OSUR, $6.09) RSI Indicator left the oversold zone on March 26, 2024

OraSure Technologies (OSUR, $6.68) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 15, 2024

This is a Bearish indicator signaling OSUR's price could decline from here. Traders may explore shorting the stock or put options...

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offers oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in 2000 in and is headquartered in Bethlehem, PA.

Orasure Technologies Inc.

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$3.18
Prev Close	$3.13
Open	$3.14
Dividend Yield	0.00%
50-Day Moving Average	$3.13
Beta	1.06
Avg. Volume	536,008.19
PE Ratio	-4.65

52-Week High	$4.60
52-Week Low	$2.36
Market Capitalization	$232.58M
EPS (Annual)	-$0.262
Price to Book	0.62
Revenue Per Employee	$370,912.18
Enterprise Value/EBITDA	N/A

OSUR
Orasure Technologies Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OSUR News

OSUR Orasure Technologies Inc.